Biovalence Technologies owns a proprietary recombinant proteomic technology platform that covers around 100 different proteins with potential antiviral therapeutic. The company is looking for funding and partners to bring its one of its two antiviral molecules against Dengue to human clinical phase II while generating revenue in the US$ 16 billion pet healthcare segment. The company’s mission is to save lives by applying recent advancement in genomics and proteomics on infectious diseases that have no cure today.